In this issue:
Evaluating the VES-13 and FIL geriatric assessment
Addition of tafasitamab to lenalidomide and rituximab
BendaR versus pirtobrutinib
Pirtobrutinib compared to ibrutinib
Long-term benefits of CAR-T therapy
Likelihood of second TFR
Safety, toxicity and immunogenicity of iTAC-XS15-CLL01
ALO compared to ALR
Prevalence, severity and reversibility of SNHL
Efficacy and tolerability of peg-IFNα plus nilotinib
Please login below to download this issue (PDF)